Promising Potential of Oruka Therapeutics’ ORKA-001 in Psoriasis Treatment
Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) and keeping the price target at ...
Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15%
Key Insights Institutions' substantial holdings in Oruka Therapeutics implies that they have significant influence ...
Oruka Therapeutics (ORKA) Gets a Buy from TD Cowen
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Oruka Therapeutics (ORKA – Research Report) today. The company’s shares closed ...
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Recommendation of “Buy” by Analysts
Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) have earned a consensus rating of “Buy” from the eight ...
Nasdaq1mon
Oruka Therapeutics reports Q3 EPS ($1.46), consensus (40c)
Chief Executive Officer of Oruka. “We are excited to soon transition to a clinical stage company and show the potential of our programs to raise the bar on what is possible in psoriatic disease.” ...
Investing25d
Oruka Therapeutics gains approval for preferred stock conversion
Oruka Therapeutics, Inc., a company specializing in diagnostic substances, announced the approval of key proposals at its Special Meeting of Stockholders held on November 14, 2024. The ...
U.S. News & World Report5mon
9 Short Squeeze Stocks That Could Take Off
The stock jumped in April 2024 after Arca announced a merger with Oruka Therapeutics, a private, clinical-stage biotech company focused on treating chronic skin diseases, including plaque psoriasis.